A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors.

ABSTRACT:

Introduction

Standard-of-care systemic chemotherapies for pancreatic ductal adenocarcinoma (PDAC) currently have limited clinical benefits, in addition to causing adverse side effects in many patients. One factor known to contribute to the poor chemotherapy response is the poor drug diffusion into PDAC tumors. Novel treatment methods are therefore drastically needed to improve targeted delivery of treatments. Here, we evaluated the efficacy of the 3DNA® Nanocarrier (3DNA) platform to direct delivery of therapeutics to PDAC tumors in vivo.

Materials and methods

A panel of PDAC cell lines and a patient tissue microarray were screened for established tumor-specific proteins to identify targeting moieties for active targeting of the 3DNA. NRG mice with or without orthotopic MIA

SUBMITTER: McCarthy GA 

PROVIDER: S-EPMC10068615 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature